EGFR and non-small cell lung carcinoma: A recent retrospective analysis in NSCLC showed no survival gain in patients who underwent genomic profiling using multi-gene targeted panels compared to patients who underwent only single-gene testing of EGFR and ALK genes, with panel testing offering additional opportunities for targeted therapy to fewer than 5% of patients [31].